Graduate School of Cancer Science and Policy, National Cancer Center, South Korea
Dr. Ho Lee is a renowned professor and researcher in cancer biomedical science, currently serving as a professor at the Graduate School of Cancer Science and Policy at the National Cancer Center (NCC), Korea. He is a prominent figure in the field of cancer research, focusing on functional studies of cancer-related genes using mouse models and nonclinical studies of anti-cancer drug candidates. With extensive experience in academia and scientific research, Dr. Lee continues to contribute to advancing cancer therapies and understanding cancer biology. 📚🔬
Profile
Orcid
Education
Dr. Lee completed his Ph.D. in Biological Sciences from Seoul National University in 2001. Prior to that, he earned his M.S. and B.S. degrees in Microbiology from the same institution. His strong academic background paved the way for his remarkable career in cancer research. 🎓📖
Professional Experience
Dr. Lee’s career spans across multiple prestigious roles. He has been serving as a professor and chair at the Graduate School of Cancer Science and Policy at NCC since 2015. In 2023, he became the director of the NCCGCSP R&D Business Foundation. He has also worked as the chief of the Laboratory Animal Research Facility at NCC, Korea, and has held key roles in international research such as his time as a visiting scientist at the Mayo Clinic. 🏫💼
Research Interests
Dr. Lee’s research interests include the functional studies of cancer-related genes using mouse models and nonclinical studies of anti-cancer drug candidates. His research aims to improve cancer treatment by better understanding molecular mechanisms and developing innovative therapeutic approaches. 🧬💉
Awards
Dr. Lee has received numerous awards and recognitions for his outstanding contributions to cancer research. His work in advancing cancer therapy and understanding the molecular biology of cancer has made him a leading figure in his field. 🏅🌟
Publications
MH Kim, MK Park, HN Park, SM Ham, H Lee, ST Lee** (2025). Anti-PTK7 Monoclonal Antibodies Suppresses Oncogenic Phenotypes in Cellular and Xenograft Models of Triple-Negative Breast Cancer. Cells. (Accepted)
JY Jang, MK Park, CH Lee, H Lee (2024). The Multifaceted Role of Epithelial Membrane Protein 2 in Cancer: from Biomarker to Therapeutic Target. Biomol Ther (Seoul) 32:697-707.
S Vadevoo, Y Kang, GR Gunassekaran, SM Lee, MS Park, DG Jo, SK Kim, H Lee, WJ Kim, B Lee (2024). IL4 receptor targeting enables nab-paclitaxel to enhance reprogramming of M2-type macrophages into M1-like phenotype via ROS-HMGB1-TLR4 axis and inhibition of tumor growth and metastasis. Theranostics 14:2605-2621.
Ka NL, Park MK, Kim SS, Jeon Y, Hwang S, Kim SM, Lim GY, Lee H, and Lee MO** (2023). NR1D1 enhances antitumor immune responses via cGAS/STING signaling pathway in breast cancer. Cancer Res 18:3045-3058.
Conclusion
Dr. Ho Lee is undeniably a highly qualified candidate for the Best Researcher Award, owing to his groundbreaking work in cancer research, impressive publication record, and leadership in the field. His innovative approach to cancer therapeutics and tumor biology, combined with his prestigious affiliations and extensive academic background, firmly positions him as a deserving nominee for the award. Further interdisciplinary collaborations could amplify his already significant impact in cancer science.